Diabetic kidney disease (DKD) remains a major global health burden and the most common cause of end-stage kidney disease. The therapeutic landscape has profoundly shifted from a glucocentric model to a multifaceted strategy focusing on the holistic management of cardiovascular-kidney-metabolic syndrome (CKM). This therapeutic paradigm is now anchored by four foundational pillars: renin-angiotensin-aldosterone system inhibitors (RAASi), sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and non-steroidal mineralocorticoid receptor antagonists (ns-MRAs), which collectively target complementary pathogenic pathways to slow DKD progression and reduce cardiovascular morbidity. Despite these advances, a high residual risk persists, driving kidney disease research into novel therapeutic targets. A large body of mechanistic studies demonstrates the critical roles of genetic and epigenetic modifications, persistent metabolic dysfunction, and inflammatory and fibrotic processes in DKD pathogenesis. Consequently, emerging investigational therapies are focused on histone-modifying enzymes, drugs to restore metabolic/lipid disorders, new anti-inflammatory and anti-fibrosis therapies, as well as stem cell-based interventions for their regenerative and immunomodulatory potential. The future of DKD management hinges on the successful clinical translation of these novel therapeutic approaches, which will require overcoming challenges in clinical trial design alongside current therapies, patient stratification for different therapeutic regimens using predictive biomarkers, and the exploration of synergistic combination therapies to ultimately personalize treatment strategies and enhance long-term kidney outcomes.
Hu et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: